research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
Search
for
Sort by
Research
600-630 / 1000+ results research A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
research Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report
Upadacitinib successfully treated a child's severe skin and hair loss issues.
research Complete hair regrowth in a patient with severe alopecia areata treated with deucravacitinib
Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.
research Upadacitinib in concurrent Crohn's disease, atopic dermatitis and alopecia areata: A case report
Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
research Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis
Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
research The α-Lipoic acid derivative sodium zinc dihydrolipoylhistidinate reduces chemotherapy-induced alopecia in a rat model: A pilot study
A substance called sodium zinc dihydrolipoylhistidinate can significantly reduce hair loss caused by chemotherapy in rats.
research JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
![Discovery of 7-Methoxy-6-[4-(4-Methyl-1,3-Thiazol-2-yl)-1H-Imidazol-5-yl]-1,3-Benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia](/images/assets/9620bd26-3366-4f2a-bcac-f511697bbc41/small/35997.jpg)
research Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia
A new compound shows promise as a topical treatment for hair loss.
research Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials
Deuruxolitinib and baricitinib are effective for treating severe alopecia areata.
research Old drug new indication: Tofacitinib for a new crop of hair?
Tofacitinib might be used to treat hair loss.
research SnapshotDx Quiz: March 2016
JAK inhibitors may help treat alopecia areata by reversing hair loss.
research Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient
Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Image 1_Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata.pdf
Farudodstat can prevent hair follicle immune damage linked to alopecia areata.
research Inhibidor janus kinasa como opción terapéutica en alopecia areata. Reporte de caso
Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
research Janus kinase inhibitors for alopecia areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research Hair Growth Promoting Effects of 15-Hydroxyprostaglandin Dehydrogenase Inhibitor in Human Follicle Dermal Papilla Cells
The inhibitor DPP can promote hair growth.
research Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
research Deuruxolitinib for Alopecia Areata.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
research Steroid sulfatase inhibitors
Steroid Sulfatase inhibitors show promise in treating hormone-dependent disorders like cancers, hair loss, and acne, with 667COUMATE being a potential candidate for breast cancer treatment trials.
research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
research Alopecia universalis. Partial response to tofacitinib
Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
research Review of Promising Off-Label Use of Deucravacitinib
Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
research ISID1116 – Novel androgen receptor degrader for androgenetic alopecia (AGA) application
research Partial Proteasome Inhibitors Induce Hair Follicle Growth by Stabilizing β-Catenin
Certain inhibitors applied to the skin can promote hair growth by maintaining a key hair growth signal.
research Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist
The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.
research Treatment of Alopecia Areata with Simvastatin/Ezetimibe
Simvastatin/ezetimibe may help treat new cases of alopecia areata but not long-term cases.
research Hair loss and Hedgehog inhibitors: a class effect?
Hedgehog pathway inhibitors used for skin cancer can cause significant hair loss, which may improve after stopping the medication.
research 766 H3K9me3 methyltransferase SETDB1 controls retrotransposon silencing, DNA methylation, constitutive heterochromatin maintenance and 3D-chromatin structure in epidermal keratinocytes
SETDB1 is essential for controlling DNA methylation, silencing retrotransposons, and maintaining skin cell health, with its absence leading to skin inflammation and hair loss.